Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol 2010; 89: 607–612. doi: 10.1007/s00277-009-0887-3.
Collins PW, Hirsch S, Baglin TP, et al, Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation, Blood 2007; 109(5): 1870–1877. doi: 10.1182/blood-2006-06-029850.
Biting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinol 2009; 20: 517–523. doi: 10.1097/MBC.0b013e32832ca388.
Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566–575. doi: 10.3324/haematol.2008.001743.
Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10(4), 622–631. doi: 10.1111/j.1538-7836.2012.04654.x.
Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105(7): 1791–1801. doi: 10.3324/haematol.2019.230771.
Perotti-Abad J-A, Cabezas-Corado A, Astolfi-Labrador L, et al. Acquired hemophilia A: a case report and review of the literature. J Med Case Rep 2025; 19(1): 354. doi: 10.1186/s13256-025-05406-9.
Haider MZ, Anwer F. Acquired Hemophilia. [Updated 2022 Dec 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from https://www.ncbi.nlm.nih.gov/books/NBK560494/.
Kamel K, Infirri SS, Riddell A, Chowdary P, Batty P. Factor VIII antibodies demonstrate type I or type II kinetics in acquired haemophilia A. Haemophilia 2025; 31(2): 313–318. doi: 10.1111/hae.15144.
Binet Q, Lambert C, Sacré L, Eeckhoudt S, Hermans C. Successful management of acquired hemophilia A associated with bullous pemphigoid: A case report and review of the literature. Case Rep Hematol, 2017; 2017: 2057019. doi: 10.1155/2017/2057019.
Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125(7): 1091–1097. doi: 10.1182/blood-2014-07-587089.
Saito M, Kanaya M, Izumiyama K, et al. Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases. Int J Gen Med 2016; 9: 393–399. doi: 10.2147/IJGM.S118422.
Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92: 66–72. doi: 10.3324/haematol.10553.
Schep SJ, van Dijk WEM, Beckers EAM, et al; Dutch Society of Haemophilia Treaters, The Netherlands. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. Am J Hematol 2021; 96(1): 51–59. doi:10.1002/ajh.26009.